Whalen Wealth Management Inc. Makes New $257,000 Investment in Insulet Co. (NASDAQ:PODD)

Whalen Wealth Management Inc. purchased a new stake in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 986 shares of the medical instruments supplier’s stock, valued at approximately $257,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC lifted its holdings in Insulet by 295.9% in the fourth quarter. SG Americas Securities LLC now owns 23,892 shares of the medical instruments supplier’s stock valued at $6,237,000 after acquiring an additional 17,857 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Insulet by 1.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after purchasing an additional 43 shares during the last quarter. Sheets Smith Wealth Management lifted its stake in shares of Insulet by 37.2% in the 4th quarter. Sheets Smith Wealth Management now owns 1,371 shares of the medical instruments supplier’s stock worth $358,000 after purchasing an additional 372 shares during the period. Trust Asset Management LLC purchased a new position in shares of Insulet in the fourth quarter worth approximately $211,000. Finally, Diversify Wealth Management LLC boosted its holdings in shares of Insulet by 51.2% in the fourth quarter. Diversify Wealth Management LLC now owns 2,762 shares of the medical instruments supplier’s stock worth $751,000 after buying an additional 935 shares during the last quarter.

Insulet Price Performance

PODD stock opened at $278.89 on Thursday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company’s fifty day moving average price is $266.52 and its 200-day moving average price is $234.38. Insulet Co. has a one year low of $160.19 and a one year high of $282.86. The company has a market capitalization of $19.56 billion, a PE ratio of 47.76, a price-to-earnings-growth ratio of 3.47 and a beta of 1.22.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 EPS for the quarter, topping the consensus estimate of $0.77 by $0.13. The business had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $518.50 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. During the same quarter in the previous year, the company earned $0.71 EPS. On average, equities analysts anticipate that Insulet Co. will post 3.22 EPS for the current fiscal year.

Insider Activity

In other Insulet news, EVP Eric Benjamin sold 12,394 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. The trade was a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

PODD has been the topic of several recent research reports. Sanford C. Bernstein assumed coverage on shares of Insulet in a research report on Wednesday, November 6th. They issued an “outperform” rating and a $300.00 price target on the stock. Canaccord Genuity Group raised their target price on Insulet from $269.00 to $304.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Barclays boosted their price target on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Citigroup raised their price objective on Insulet from $283.00 to $310.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, TD Cowen boosted their price objective on Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and a consensus target price of $272.81.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.